REG - Oxford Biomedica PLC - John Dawson to retire from Oxford Biomedica

Oxford BioMedicaAnnouncement

17/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220117:nRSQ5600Ya&default-theme=true

RNS Number : 5600Y  Oxford Biomedica PLC  17 January 2022

 

John Dawson to retire from Oxford Biomedica

Oxford, UK - 17 January 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group" or "the Company") a leading gene and cell therapy
company, today announces that, after more than 13 years of service, John
Dawson, Chief Executive Officer, has signalled to the Board his intention to
retire from the Company. Accordingly, the Board has initiated a formal search
for a successor.

 

Dr. Roch Doliveux, Chairman of Oxford Biomedica, commented: "John has
provided more than 13 years of dedicated service and leadership to Oxford
Biomedica and, on behalf of the Board and all of our staff, we thank him
wholeheartedly. His successful career with the Company was underlined very
recently by a much-deserved CBE awarded for services to UK Life Science. Under
his leadership, together with the strong senior executive team, Oxford
Biomedica has grown into an industry leader in lentiviral vectors, delivered
multiple partnerships and successfully manufactured life-saving COVID-19
vaccine, all due to the expertise and robustness of the Company's management
team. We have commenced a formal process to appoint a successor who will lead
the Group through its next phase of growth whilst also ensuring the Company
remains fully focussed on the execution of its strategy of delivering life
changing gene therapies to patients."

 

John Dawson, Chief Executive Officer of Oxford Biomedica, added: "I am
immensely proud of Oxford Biomedica's achievements, and will retire at the
appropriate time. Oxford Biomedica is now a global market leader in viral
vector technologies for gene and cell therapy. The world-class management team
at Oxford Biomedica is surrounded by a dedicated workforce of over 740 people
who have demonstrated a unique robustness and ability to deliver
– exemplified several times over the recent years and certainly by our
contribution to the fight against the pandemic. I believe this is the right
time to start the transition to a new leader given the robustness of the
senior team and Company as a whole, which is undoubtedly stronger than ever
before."

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which
the Group leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary portfolio of gene
and cell therapy product candidates in the areas of oncology, CNS disorders
and liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Arcellx and
Cabaletta Bio, through which it has long-term economic interests in other
potential gene and cell therapy products. Additionally, the Group has signed a
3-year master supply and development agreement with AstraZeneca for
large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK
and employs more than 740 people. Further information is available at
www.oxb.com (http://www.oxb.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFFFILLAIRLIF